23andMe Holding Co. (ME) Free Cash Flow Yield: N/A
The free cash flow yield for 23andMe Holding Co. (ME) is N/A as of Monday, June 15, 2026.
ME Free Cash Flow Yield Chart
ME Average Free Cash Flow Yield Chart
ME Free Cash Flow Yield Metrics
FREE CASH FLOW YIELD
N/A
FREE CASH FLOW YIELD AVG TTM
-496.25%
FREE CASH FLOW YIELD AVG 3Y
-255.12%
FREE CASH FLOW YIELD AVG 5Y
-171.49%
FREE CASH FLOW YIELD AVG 10Y
N/A
FREE CASH FLOW YIELD AVG 15Y
N/A
FREE CASH FLOW YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ME Competitors' Free Cash Flow Yield
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | N/A | -496.25% | -255.12% | -171.49% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.02B | 5.16% | 5.05% | 5.60% | 5.60% |
| Hims & Hers Health, Inc. (HIMS)vs › | $5.98B | 1.24% | 1.43% | 1.61% | 1.61% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.73B | 4.63% | 4.52% | 3.11% | 2.79% |
| Tempus AI, Inc. (TEM)vs › | $8.35B | N/A | -3.09% | -3.23% | -3.23% |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | 4.26% | 6.29% | 5.02% | 4.15% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 5.60% | 5.84% | 5.45% | 8.51% |
| Baxter International Inc. (BAX)vs › | $10.77B | 6.64% | 3.18% | 3.92% | 3.74% |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 5.48% | 5.42% | 3.77% | 3.05% |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 4.30% | 3.02% | 1.90% | 2.24% |
Yield Comparison
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
- Shows free cash flow after capital expenditures relative to market cap
- Can be compared with earnings yield and dividend yield
- Can be compared with the company's historical range
- Can be compared with peers that report positive free cash flow
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
23andMe Holding Co. Free Cash Flow Yield Formula & Definition
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. Free Cash Flow Yield FAQ
- What is the free cash flow yield for 23andMe Holding Co. (ME)?
- The free cash flow yield for ME stock is N/A.
- What is the TTM average free cash flow yield for 23andMe Holding Co. (ME)?
- The TTM average free cash flow yield for ME stock is -496.25%.
- What is the 3Y average free cash flow yield for 23andMe Holding Co. (ME)?
- The 3Y average free cash flow yield for ME stock is -255.12%.
- What is the 5Y average free cash flow yield for 23andMe Holding Co. (ME)?
- The 5Y average free cash flow yield for ME stock is -171.49%.
23andMe Holding Co. Free Cash Flow Yield History
| DATE | FREE CASH FLOW YIELD |
|---|---|
| 2025-03-31 | -924.20% |
| 2024-03-31 | -68.29% |
| 2023-03-31 | -17.16% |
| 2022-03-31 | -10.81% |
| 2021-03-31 | -1.97% |
| 2020-03-31 | -6.51% |
| 2019-03-31 | -3.16% |
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage